Globe Newswire (Wed, 18-Mar 2:25 PM ET)
Business Wire (Wed, 18-Mar 1:37 PM ET)
Newsfile (Tue, 17-Mar 9:12 PM ET)
Business Wire (Tue, 17-Mar 4:00 PM ET)
Globe Newswire (Tue, 17-Mar 3:49 PM ET)
Globe Newswire (Tue, 17-Mar 2:51 PM ET)
Business Wire (Tue, 17-Mar 2:37 PM ET)
PRNewswire (Tue, 17-Mar 9:00 AM ET)
Globe Newswire (Tue, 17-Mar 8:18 AM ET)
TipRanks (Tue, 17-Mar 6:15 AM ET)
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Nektar Therapeutics trades on the NASDAQ stock market under the symbol NKTR.
As of March 18, 2026, NKTR stock price climbed to $75.41 with 302,052 million shares trading.
NKTR has a beta of 3.59, meaning it tends to be more sensitive to market movements. NKTR has a correlation of 0.16 to the broad based SPY ETF.
NKTR has a market cap of $2.11 billion. This is considered a Mid Cap stock.
Last quarter Nektar Therapeutics reported $22 million in Revenue and -$1.78 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $1.42.
In the last 3 years, NKTR traded as high as $77.00 and as low as $6.19.
The top ETF exchange traded funds that NKTR belongs to (by Net Assets): VTI, VXF, SCHA, XPH, IHE.
NKTR has outperformed the market in the last year with a price return of +452.9% while the SPY ETF gained +18.7%. NKTR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +66.0% and +10.7%, respectively, while the SPY returned -0.5% and -2.1%, respectively.
NKTR support price is $71.37 and resistance is $78.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NKTR shares will trade within this expected range on the day.
